Characteristics of patients diagnosed with non–small-cell lung cancer before and during the COVID-19 pandemic who underwent surgery
| Characteristic | Period; no. (%) of patients* | p value | ||
|---|---|---|---|---|
| Before COVID-19 pandemic† n = 330 | During COVID-19 pandemic‡ n = 320 | Overall n = 650 | ||
| Sex | 0.4 | |||
| Male | 138 (41.8) | 124 (38.8) | 262 (40.3) | |
| Female | 192 (58.2) | 196 (61.2) | 388 (59.7) | |
| Age, mean ± SD, yr | 68.8 ± 9.2 | 68.7 ± 10.1 | 68.8 ± 9.6 | 0.8 |
| Body mass index, mean ± SD | 28.1 ± 5.9 | 28.0 ± 6.2 | 28.1 ± 6.0 | 0.8 |
| Smoking history | 0.1 | |||
| Never smoked | 31 (9.4) | 47 (14.7) | 78 (12.0) | |
| Past smoker | 187 (56.7) | 177 (55.3) | 364 (56.0) | |
| Current smoker | 111 (33.6) | 96 (30.0) | 207 (31.8) | |
| Missing | 1 (0.3) | 0 (0.0) | 1 (0.2) | |
| Alcohol use | 0.06 | |||
| No | 131 (39.7) | 150 (46.9) | 281 (43.2) | |
| Yes | 199 (60.3) | 168 (52.5) | 367 (56.5) | |
| Missing | 0 (0.0) | 2 (0.6) | 2 (0.3) | |
| FEV1, mean ± SD, % | 82.1 ± 19.9 | 84.5 ± 23.2 | 83.2 ± 21.6 | 0.2 |
| DLCO, mean ± SD, % | 74.7 ± 20.3 | 78.0 ± 70.3 | 76.3 ± 51.0 | 0.4 |
| No. of pulmonary comorbidities | 1.0 | |||
| 0 | 179 (54.2) | 173 (54.1) | 352 (54.2) | |
| ≥ 1 | 151 (45.8) | 147 (45.9) | 298 (45.8) | |
| No. of other comorbidities | 1.0 | |||
| 0 | 103 (31.2) | 100 (31.2) | 203 (31.2) | |
| ≥ 1 | 227 (68.8) | 220 (68.8) | 447 (68.8) | |
| ECOG Performance Status Scale grade,§ mean ± SD | 0.73 ± 0.66 | 0.59 ± 0.75 | 0.67 ± 0.71 | 0.02 |
| CCI score, mean ± SD | 5.61 ± 1.77 | 5.95 ± 2.03 | 5.78 ± 1.91 | 0.02 |
| Survival | 0.4 | |||
| Alive | 314 (95.2) | 300 (93.8) | 614 (94.5) | |
| Deceased | 16 (4.8) | 20 (6.2) | 36 (5.5) | |
CCI = Charlson Comorbidity Index; DLCO = diffusing capacity of the lung for carbon monoxide; ECOG = Eastern Cooperative Oncology Group; FEV1 = forced expiratory volume in 1 second; SD = standard deviation.
↵* Except where noted otherwise.
↵† January 2019–February 2020.
↵‡ March 2020–February 2021.
↵§ Graded from 0 (fully active) to 5 (dead).